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in trial 1 and 6% in trial 2, and total 100-day treatment-related
mortality was 13% in trial 1 and 6% in trial 2. The incidence of
chronic GVHD in the 2 trials was 49% and 44%, respectively. At
2 years, the relapse-free and overall survival estimates for trial 1 are
46% and 48%, respectively (median follow-up, 27 months). One
year relapse-free and overall survival estimates for trial 2 are 71%
and 75%, respectively (median follow-up, 11 months). Overall
survival at 2 years is 72%. Conclusions: Sirolimus, when added to
tacrolimus after allogeneic stem cell transplantation, is effective as
GVHD prophylaxis. Engraftment is prompt, and transplant-re-
lated morbidity and mortality is reduced. Survival estimates are
excellent due to reduced GVHD and transplant-related toxicity.
Sirolimus is worthy of broader study in allogeneic transplantation.
10
SIROLIMUS AND THROMBOTIC MICROANGIOPATHY AFTER ALLOGE-
NEIC STEM CELL TRANSPLANTATION
Cutler, C.; Henry, N.L.; Li, S.; Kim, H.T.; Magee, C.; Alyea, E.; Ho,
V.; Soiffer, R.; Antin, J. Dana Farber Cancer Institute and Brigham
and Women’s Hospital, Harvard Medical School, Boston, MA.
Sirolimus (SRL) is a novel immunosuppressive agent that can
reduce GVHD and minimize morbidity after allogeneic stem cell
transplantation (SCT). Thrombotic microangiopathy (TMA) is
characterized by microangiopathic hemolysis, thrombocytopenia,
and renal dysfunction and is associated with calcineurin inhibitors
(CIs). To determine whether SRL use potentiates the effects of CIs
on TMA incidence and risk factors, we performed a retrospective
cohort analysis of subjects who underwent SCT between 1997 and
2003. Methods: Subjects who received a SRL-containing GVHD
prophylaxis regimen were compared with a cohort who received a
non-SRL regimen. All subjects received CIs. Diagnosis of TMA
required the simultaneous occurrence of (1) creatinine elevation 
2 mg/dl or  50% above baseline, (2) schistocytosis, (3) elevated
LDH, and (4) no evidence of DIC. Results: The 111 patients who
received SRL were compared with 216 patients who received no
SRL. The 2 groups of patients were balanced for demographic
parameters; however, more patients in the SRL group received
PBSC transplants (50.5 vs 18.1%; P  .01) and had unrelated
donors (58.6 vs 42.6%, P  .01). The incidence of TMA was
higher in the SRL group than in the non-SRL group (10.8% vs
4.2%; OR  2.57, P  .03). SRL patients developed TMA earlier
than did non-SRL patients (median, 25 days vs 58 days; P  .04).
At TMA diagnosis, median blood levels of immunosuppressive
medications were all within their respective therapeutic ranges. In
a multivariable logistic regression model, only the use of SRL
(adjusted exact OR  3.49, P  .02) and grade II-IV acute GVHD
(adjusted exact OR  6.60, P  .0002) predicted the occurrence of
TMA. Treatment of TMA consisted of discontinuation or dose
adjustment of CIs and SRL. Two subjects in each group required
temporary hemodialysis, and 3 subjects (1 SRL, 2 non-SRL) un-
derwent plasmapheresis. A total of 78% of surviving SRL-treated
subjects regained normal renal function. No subject had a TMA
recurrence if SRL was reintroduced. CIs were never reintroduced.
Overall survival after TMA diagnosis was better for SRL patients
than for non-SRL patients (58.3% vs 11.1%; log rank P  .02).
Conclusion: SRL is associated with an increased risk of TMA after
SCT and may act by potentiating the effects of CIs. TMA associ-
ated with SRL appears to be reversible and does not affect overall
survival after SCT. A careful monitoring strategy for TMA should
be used as part of a SRL-containing GVHD prophylaxis regimen.
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PALIFERMIN (A RHUKGF MOLECULE) IS SAFE AND WELL TOLERATED
IN PATIENTS WITH HEMATOLOGIC MALIGNANCIES (HM) UNDERGO-
ING HIGH-DOSE CHEMORADIOTHERAPY (HD-CRT) FOLLOWED BY AL-
LOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT)
Blazar, B.R.1; Weisdorf, D.J.1; DeFor, T.E.1; Goldman, A.I.1; Silver,
S.2; Ferrara, J.L.M.2 1. University of Minnesota, Minneapolis, MN; 2.
University of Michigan, Ann Arbor, MI.
The major limitation of allogeneic HSCT is graft-versus-host-
disease (GVHD), a complication where the skin, gastrointestinal
(GI) tract, and liver are damaged by cytokine effectors. Palifermin
has a growth-enhancing differentiation and cytoprotective effect in
the oral and GI mucosa and may be useful as a GVHD prophylaxis.
Previously, we demonstrated that palifermin signiﬁcantly reduced
the incidence, duration, and severity of oral mucositis (OM) in the
autologous HSCT setting. Two animal studies demonstrated pali-
fermin could prevent mucositis and GVHD after CRT. In this
investigator-initiated, randomized, double-blind, placebo-con-
trolled, dose-escalation trial, the safety of palifermin administra-
tion to HM patients undergoing HD-CRT following by allogeneic
HSCT was evaluated. Methods: Patients were entered into 1 of 3
sequentially-enrolled dose/schedule cohorts involving administra-
tion of study drug (placebo or palifermin) on days 11, 10, 9,
0, 1, and 2 relative to HSCT (day 0). Three additional doses were
given to each sequential cohort: stage 1 (3 pretreatment/3 post-
treatment), stage 2 (3 pretreatment/6 posttreatment), or stage 3 (3
pretreatment/9 posttreatment). Adverse events (AEs) were col-
lected continuously. Patients were followed for safety for 100 days
and for survival/relapse for 1 year. Results: A total of 100 patients
(31 placebo, 69 palifermin [8 receiving 40 g/kg/day and 61 re-
ceiving 60 g/kg/day]) were randomized to stage 1, 2, or 3. Time
to engraftment for ANC and platelets was similar between treat-
ment groups. No signiﬁcant differences in the incidence or severity
of GVHD, survival, or relapse rates were observed between treat-
ment groups. Overall, 20 patients (2 placebo, 18 palifermin) dis-
continued the study. Of these, 6 patients (2 placebo, 4 palifermin)
experienced a total of 11 dose-limiting toxicities (DLTs). Discon-
tinuations and DLTs were most common in patients who received
at least 6 doses of study drug after engraftment (day 0). Eighteen
patients (5 placebo, 13 palifermin) died before day 100, due pri-
marily to treatment complications. Palifermin appeared to have a
beneﬁcial effect on OM, but no effect was observed on diarrhea.
Conclusion: Palifermin administration in the allogeneic treatment
setting was safe and well tolerated and did not have any negative
effects on engraftment, GVHD, or survival rates.
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ADOPTIVE TRANSFER OF IN VITRO-GENERATED T CELL PRECURSORS
ENHANCES POSTTRANSPLANT DONOR T CELL RECONSTITUTION IN
RECIPIENTS OF AN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANS-
PLANTATION
Zakrzewski, J.L.1; Kochman, A.1; Muriglan, S.J.1; Lu, S.1; Kim,
T.D.1; Zuniga-Pﬂucker, J.C.2; Alpdogan, O.1; van den Brink, M.R.M.1
1. Memorial Sloan Kettering Cancer Center, New York, NY; 2. Sun-
nybrook and Women’s College Health Sciences Centre, University of
Toronto, Toronto, ON, Canada.
Recent studies have shown that murine T cells and their precur-
sors can be generated from hematopoietic stem cells (HSC) in vitro
using a novel OP9-DL1 co-culture system consisting of OP9 bone
marrow stromal cells expressing Delta-like 1 Notch ligand (which
binds to the Notch 1 receptor) and growth factors (interleukin 7
and fms-like tyrosine kinase-3 ligand). In this study we determined
the effects of ex vivo-generated T cell precursors on T cell recon-
stitution after allo HSCT. We selected Lin-, Sca-1hi, and c-kithi
HSC from donor bone marrow and cultured these on a monolayer
of OP9-DL1 cells in the presence of growth factors. These
HSC expanded 850-5000-fold and consisted of 95% CD4-CD8
double-negative (DN) T cell precursors after 16–28 days of
culture. We infused these cells (8  106) with T-cell- depleted
(TCD) BM (5  106) into allogeneic recipients. Control mice
received TCD BM only. To determine the effects on T cell
reconstitution after allo HSCT we analyzed thymi and spleens
at days 14 and 29 after transplant by ﬂow cytometry. Progeny
of OP9-DL1 T cell precursors was found on days 14 and 29 in
both thymus and spleen, including 40% (	 20%) of thymo-
cytes and 25% (	 9%) of splenic T cells on day 14 posttrans-
plant and 3.6% (	 2.4%) of thymocytes and 33% (	 7%) of
splenic T cells on day 29 posttransplant. The thymic cellularity was
increased up to 50% on day 14 posttransplant in the OP9-DL1
HSCT group compared to the control group. Splenic T cell
numbers were not increased in OP9-DL1 recipients; however,
donor T cell chimerism was enhanced signiﬁcantly 88.5% vs 65%).
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Less than 1% of CD19 and CD11b donor splenocytes origi-
nated from OP9-DL1 T-cell precursors. In our preliminary exper-
iments we did so far not observe any signs of graft-versus-host
disease (GVHD) in recipients of OP9-DL1 T-cell precursors. The
proliferative capacity of splenic T cells as determined by third-
party MLR was intact compared to controls. We conclude that the
co-culture of HSC with OP9-DL1 cells and growth factors results
in a 850- to 5000-fold expansion of  95% pure T-cell precursors,
which can home to the thymus after infusion into allo HSCT
recipients. These precursors undergo normal T-cell development,
reconstitute the periphery, proliferate to third party antigens, do
not cause GVHD, and improve donor T-cell chimerism. There-
fore, adoptive transfer of OP9-DL1 derived T-cell precursors
could signiﬁcantly enhance posttransplant T-cell reconstitution
without GVHD.
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PHASE I STUDY OF A NEUTRALIZING MONOCLONAL ANTI-CTLA4 AN-
TIBODY (MDX-010) IN PATIENTS WITH RELAPSE OF MALIGNANCY
AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
Bashey, A.1; Medina, B.1; Zhong, R.-K.1; Zhou, J.-H.1; Carrier, E.1;
Castro, J.1; Holman, P.1; Lane, T.A.1; Sun, C.1; Lowy, I.2; Cor-
ringham, S.1; Soiffer, R.4; Mason, J.3; Ball, E.D.1 1. Division of Blood
and Marrow Transplantation, Moores Cancer Center, University of
California San Diego, La Jolla, CA; 2. Medarex, Inc., Bloomsbury, NJ;
3. Scripps Clinic, La Jolla, CA; 4. Dana Faber Cancer Institute, Boston,
MA.
Relapse of malignancy remains a major cause of treatment failure
after allogeneic hematopoietic stem cell transplantation (allo-
HCT). Tumors may utilize a variety of mechanisms to evade the
adoptive immunotherapy provided by allo-HCT. These may in-
clude lack of costimulation and direct or indirect inhibition of
T-cell activation. CTLA-4 (cytotoxic T-lymphocyte-associated
antigen-4) is a homologue of CD28 that functions as a negative
regulator of T-cell activation. Blockade of CTLA-4 using neutral-
izing antibodies has demonstrated potent anticancer effects in
animal models of antitumor immunity. Tumor regression as well as
autoimmune phenomena have been seen in phase I/II clinical trials
of CTLA-4 blockade in advanced solid tumors. Although CTLA-4
blockade may augment graft-versus-malignancy after allo-HCT,
GVHD and other immune complications may also be increased.
We have conducted a phase I dose-escalation trial of a neutralizing
human monoclonal anti-CTLA-4 antibody (MDX-010) in patients
with relapse of malignancy after allo-HCT. Eligibility criteria
included allo-HCT  90 days previously,  50% donor T-cell
chimerism, no prior grade 3/4 GVHD, and no prophylaxis/therapy
for GVHD for  6 weeks. Eligible patients received a single dose
of MDX-010 over 90 minutes. Patients were allowed DLI at a dose
of 5  106 CD3 cells/kg 8 weeks after MDX-010 if no GVHD
occurred and progression of malignancy (PD) was present. Six
patients (3 males and 3 females; median age 44 years; 2 cases of
CML, 1 case of AML, 1 case of myeloma, 1 case of renal carci-
noma, 1 case of breast cancer) have been treated (4 at a dose level
of 0.1 mg/kg, 3 at a dose level of 0.33 mg/kg). MDX-010 was well
tolerated in this setting; no infusional toxicity was seen. No patient
has developed clinically signiﬁcant exacerbation of GVHD or new-
onset GVHD after infusion. One patient (dose, 0.1 mg/kg) devel-
oped a grade 3 polyarthropathy with rheumatoid nodules 14 weeks
after MDX-010 and 6 weeks post-DLI, which resolved with cor-
ticosteroid therapy. No other autoimmune complications were
seen. MTD has not been reached. Two patients have demonstrated
possible anticancer responses (ie, partial remission of AML refrac-
tory to prior therapies, molecular remission of CML maintained
off imatinib). With a median follow-up of 164 days, 1 patient has
died (PD), 5 patients are alive, and 1 patient is in CR. Pharmaco-
kinetic and correlative science data will be presented. This study
shows safety with possible antitumor effects at the dose levels
tested.
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A PILOT STUDY EVALUATING THE SAFETY AND EFFICACY OF AMD3100
FOR THE MOBILIZATION AND TRANSPLANTATION OF HLA-MATCHED
SIBLING DONOR HEMATOPOIETIC STEM CELLS IN PATIENTS WITH
ADVANCED HEMATOLOGICAL MALIGNANCIES
Andritsos, L.A.1; Edwards, T.1; Sempek, D.1; Calandra, G.2; Badel,
K.2; Vij, R.1; DiPersio, J.F.1; Devine, S.M.1 1. Washington University
School of Medicine, St Louis, MO; 2. Anormed Inc., Langley, BC,
Canada.
Cytokine-mobilized peripheral blood (MPB) has become the
preferred allograft source for patients with advanced hematological
malignancies. Procurement of MPB currently requires from 5 to 6
days of granulocyte colony-stimulating factor (G-CSF) adminis-
tration and is associated with donor morbidity and high cost.
Recent studies suggest G-CSF induces mobilization by indirectly
targeting the interaction between the chemokine stromal derived
factor 1 (SDF-1) and its receptor CXCR-4. Here we report pre-
liminary results using a direct antagonist of the SDF-1/CXCR-4
interaction, AMD3100, as a single agent to procure MPB from
allogeneic donors in only 1 or 2 days. Four HLA-identical siblings,
all males ranging from 40 to 58 years old, received 1 or 2 doses of
AMD3100 at 240 g/kg, followed 4 hours later by leukapheresis
(LP). After collection and a 1-week washout period, the same
donors were remobilized using G-CSF at 10 g/kg/day, followed
by LP commencing on day 5. The target CD34 cell dose fol-
lowing each agent was  2.0  106/kg recipient weight. The
results of the mobilizations and allograft composition are presented
in the table. After AMD3100, all donors tolerated treatment well,
and none experienced greater than grade 1 toxicity. All donors
experienced grade 2 bone pain during G-CSF mobilization. The
AMD3100-mobilized cells from 2 donors (donors 1 and 4) were
transplanted into a 51-year-old woman with AML and into a
48-year-old woman with NHL, respectively, after conditioning
with cyclophosphamide (120 mg/kg) and total body irradiation
(single 550-cGy dose). Both recipients engrafted neutrophils 
500/l promptly on days 10 and 11 and platelets  20,000/l
on days 14 and 20. Both patients are currently being fol-
lowed as outpatients and are without GVHD. The patient with
AML has full donor chimerism and normal trilineage hematopoi-
esis over 4 months following transplant and is in complete remis-
sion. The allografts collected from 2 donors were not given due to
progressive disease in the intended recipients. Grafts mobilized
after AMD3100 differ from G-CSF-mobilized allografts in the
content of CD34 and immune effector cells but appear to recon-
stitute hematopoiesis similarly. These preliminary data suggest
that a chemokine antagonist can safely and rapidly induce the
mobilization of a functionally competent hematopoietic allograft.
Accrual is ongoing, and additional donor/recipient pairs will be
presented.
Results of Mobilization
Agent AMD3100 AMD3100 AMD3100 AMD3100 AMD3100 G-CSF
Donor # 1 2 3 4 Combined
4
Combined
Median
Values
Median
Values
Days of drug
administration 2 1 2 2 2 5
# LP Procedures 2 1 2 2 2 1
Peak fold 1
CD34 7 6 7 5 6.5 22
CD34 dose
(106/kg) 2.6 2.1 1.2 2.5 2.3 2.9
CD3 dose
(108/kg) 4.9 1.5 2.7 3.2 3.8 1.3
CD4 dose
(108/kg) 3.1 1.0 2.0 3.2 2.5 0.8
CD8 dose
(108/kg) 1.7 0.4 0.6 3.4 1.2 0.5
CD56 dose
(107/kg) 3.4 2.1 2.7 3.7 3.1 1.9
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